Dr. Lior Shaltiel reports

NUREXONE ANNOUNCES CLOSING OF NON-BROKERED PRIVATE PLACEMENT

Nurexone Biologic Inc., subject to TSX Venture Exchange approval, has closed a non-brokered private placement of 1,012,573 units at a price of 62 cents per unit for aggregate gross proceeds of approximately $627,795.26. The company intends to use the proceeds of the offering for general working capital purposes. No insiders participated in this offering and no finders' fees were paid in connection with this offering.

Each unit consists of: (i) one common share in the capital of the company; and (ii) one common share purchase warrant. Each warrant entitles the holder thereof to purchase one common share at a price of 78 cents per common share for a period of 36 months from the closing date, subject to acceleration. If the daily volume weighted average trading price of the common shares on the TSX-V for any period of 20 consecutive trading days equals or exceeds $1.55, the company may, upon providing written notice to the holders of the warrants, accelerate the expiry date of the warrants to the date that is 30 days following the date of the acceleration notice. If the warrants are not exercised by the accelerated expiry date, the warrants will expire and be of no further force or effect.

Closing of the offering is subject to receipt of all necessary regulatory approvals, including TSX-V approval, and all securities issued under the offering are subject to a statutory hold period of four months and one day from the closing date of the offering.

About Nurexone Biologic Inc.

Nurexone is a TSX-V-, OTCQB- and Frankfurt Stock Exchange-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve damage. Regulatory milestones, including obtaining the orphan drug designation, facilitate the company's road map toward clinical trials in the United States and Europe. Commercially, the company is expected to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. Nurexone has established Exo-Top Inc., a U.S. subsidiary, to anchor its North American activity and growth strategy.

We seek Safe Harbor.